{"id":819139,"date":"2025-02-27T08:11:33","date_gmt":"2025-02-27T13:11:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/"},"modified":"2025-02-27T08:11:33","modified_gmt":"2025-02-27T13:11:33","slug":"electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/","title":{"rendered":"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">ROCKAWAY, N.J., Feb.  27, 2025  (GLOBE NEWSWIRE) &#8212; electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent\u2122\u00a0by Spark Biomedical, an FDA cleared\u00a0non-invasive transcutaneous auricular neuromodulation device available by prescription for the treatment of opioid withdrawal symptoms, will be distributed by electroCore, Inc. within certain Department of Veterans Affairs (VA) facilities.<\/p>\n<p align=\"justify\">\u201cAt Spark Biomedical, we are dedicated to pioneering drug-free, wearable neurostimulation solutions that address critical gaps in addiction treatment,&#8221; said Daniel Powell, Chief Executive Officer of Spark Biomedical, Inc. &#8220;This partnership with electroCore represents a significant step forward in expanding access to the Sparrow Ascent\u2122 within VA facilities, offering veterans a clinically validated, FDA-cleared, non-invasive treatment for opioid withdrawal symptoms. By leveraging electroCore\u2019s established distribution network, we can help more veterans begin their journey to recovery with an effective, drug-free option.\u201d<\/p>\n<p align=\"justify\">\u201cWe are thrilled to be adding the Sparrow Ascent treatment into our distribution network within the VA hospital system,\u201d commented\u00a0Dan Goldberger, Chief Executive Officer of electroCore. \u201cWe have made considerable progress building our commercial sales organization and continue to look for unique and complementary therapies which can be made available to our customer base. The drug-free, non-addictive, wearable Sparrow Ascent therapy is ideal for veterans suffering from opioid withdrawal symptoms, and we believe it will be well adopted by customers who utilize neuromodulation devices such as our existing gammaCore\u2122 therapy to treat medical conditions.\u201d<\/p>\n<p>\n        <strong>About Spark Biomedical<br \/><\/strong>Spark Biomedical, Inc. is a leading U.S.-based medical device developer, committed to unlocking the potential of bioelectronic medicine and bringing to market novel wearable neurostimulation treatment options in behavioral health, women\u2019s health, hemostasis, pediatrics, and chronic pain.<\/p>\n<p align=\"justify\">Spark leverages its neuroscience and engineering expertise to empower healthcare providers and researchers with innovative, evidence-based tools designed to address complex care situations which exceed the capabilities of existing treatment options. Spark has received funding from federal institutions, such as the NIH and DoD, and continues to partner with private and academic institutions. Spark Biomedical is empowering a better way forward for the future of patient care and medical technology.<\/p>\n<p align=\"justify\">For more information, visit sparkmedical.com.<\/p>\n<p align=\"justify\">\n        <strong>About electroCore, Inc.<\/strong><br \/>\n        <br \/>electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health and promoting general wellness through its non-invasive vagus nerve stimulation (\u201cnVNS\u201d) technology platform. The Company is focused on commercializing medical devices for managing and treating certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.<\/p>\n<p>For more information, visit www.electrocore.com.<\/p>\n<p>\n        <strong>Forward-Looking Statements<br \/><\/strong>This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore&#8217;s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the company\u2019s business prospects for distribution of Sparrow Ascent\u2122 for opioid withdrawal symptoms within certain VA facilities or other new markets or other distribution agreements and other statements that are not historical in nature, particularly those that utilize terminology such as &#8220;anticipates,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore\u2019s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore\u2122, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>ECOR Investor Relations<br \/>(973) 302-9253<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hXNCYpz4T6WWPEW_4OxkrLX0G2dAHF_axfdB0UCN6asVgZU9PnFalOD2rDxk-82myaYnt9JQ6wQDco0oaStHb9SJMDexiOYypRjrMEkwLlkeC4ZP5JhVbVFMG9x8b9Lf\" rel=\"nofollow\" target=\"_blank\">investors@electrocore.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWJiMzBhYzAtMDkxYi00Y2FhLTllNDAtMjY0ZTEyM2RmMTRjLTExMTAzMTU=\/tiny\/electroCore-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent\u2122\u00a0by Spark Biomedical, an FDA cleared\u00a0non-invasive transcutaneous auricular neuromodulation device available by prescription for the treatment of opioid withdrawal symptoms, will be distributed by electroCore, Inc. within certain Department of Veterans Affairs (VA) facilities. \u201cAt Spark Biomedical, we are dedicated to pioneering drug-free, wearable neurostimulation solutions that address critical gaps in addiction treatment,&#8221; said Daniel Powell, Chief Executive Officer of Spark Biomedical, Inc. &#8220;This partnership with electroCore represents a significant step forward in expanding access to the Sparrow Ascent\u2122 within VA facilities, offering veterans a clinically validated, FDA-cleared, non-invasive treatment for opioid withdrawal symptoms. By leveraging electroCore\u2019s &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-819139","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent\u2122\u00a0by Spark Biomedical, an FDA cleared\u00a0non-invasive transcutaneous auricular neuromodulation device available by prescription for the treatment of opioid withdrawal symptoms, will be distributed by electroCore, Inc. within certain Department of Veterans Affairs (VA) facilities. \u201cAt Spark Biomedical, we are dedicated to pioneering drug-free, wearable neurostimulation solutions that address critical gaps in addiction treatment,&#8221; said Daniel Powell, Chief Executive Officer of Spark Biomedical, Inc. &#8220;This partnership with electroCore represents a significant step forward in expanding access to the Sparrow Ascent\u2122 within VA facilities, offering veterans a clinically validated, FDA-cleared, non-invasive treatment for opioid withdrawal symptoms. By leveraging electroCore\u2019s &hellip; Continue reading &quot;electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-27T13:11:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal\",\"datePublished\":\"2025-02-27T13:11:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/\"},\"wordCount\":731,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/\",\"name\":\"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=\",\"datePublished\":\"2025-02-27T13:11:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/","og_locale":"en_US","og_type":"article","og_title":"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal - Market Newsdesk","og_description":"ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) &#8212; electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent\u2122\u00a0by Spark Biomedical, an FDA cleared\u00a0non-invasive transcutaneous auricular neuromodulation device available by prescription for the treatment of opioid withdrawal symptoms, will be distributed by electroCore, Inc. within certain Department of Veterans Affairs (VA) facilities. \u201cAt Spark Biomedical, we are dedicated to pioneering drug-free, wearable neurostimulation solutions that address critical gaps in addiction treatment,&#8221; said Daniel Powell, Chief Executive Officer of Spark Biomedical, Inc. &#8220;This partnership with electroCore represents a significant step forward in expanding access to the Sparrow Ascent\u2122 within VA facilities, offering veterans a clinically validated, FDA-cleared, non-invasive treatment for opioid withdrawal symptoms. By leveraging electroCore\u2019s &hellip; Continue reading \"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-27T13:11:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal","datePublished":"2025-02-27T13:11:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/"},"wordCount":731,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/","name":"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=","datePublished":"2025-02-27T13:11:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM4NDM0NyM2Nzc3NzAyIzIwOTg3NDQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/electrocore-inc-announces-agreement-with-spark-biomedical-inc-to-distribute-sparrow-ascent-for-opioid-withdrawal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=819139"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/819139\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=819139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=819139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=819139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}